Short answer
Regeneron Pharmaceuticals (REGN) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial and operating results announced for quarter ended March 31, 2026.
Regeneron Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial and operating results announced for quarter ended March 31, 2026
- Exhibit 99.1 contains the substantive earnings release for detailed investor review
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenues rose 19% to $3.605B and non-GAAP EPS increased 15% to $9.47, signaling strong operating momentum
- Dupixent collaboration revenue reached $1.605B, with global net sales up 33% to $4.9B
- EYLEA transition accelerating: EYLEA HD sales up 52% to $468M, while combined EYLEA sales declined 10% to $941M
- GAAP gross-margin guidance cut to 77%–78% from 79%–80% due to Limerick manufacturing interruption and related costs
- New $3.0B repurchase authorization plus $803M repurchased in Q1 strengthens shareholder returns; Otarmeni approval adds gene-therapy platform optionality
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Regeneron Pharmaceuticals 8-K filings
Get the next REGN 8-K as it lands
Follow REGN for push alerts, or ask the research agent what this filing means.